Product Description
Cediranib is a potent small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor of all three VEGF receptors (VEGFR-1, 2 and 3) at nanomolar concentrations. (Sourced from: https://nciformulary.cancer.gov/available_agents/Cediranib.htm)
Mechanisms of Action: VEGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Puerto Rico, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Adenocarcinoma|Clear Cell Adenocarcinoma|Colorectal Cancer|Endometrial Cancer|Endometrioid Carcinoma|Leiomyosarcoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma|Transitional Cell Carcinoma|Uterine Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DAPPER | P2 |
Active, not recruiting |
Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma|Leiomyosarcoma |
2025-01-01 |
|
| NCI-2017-01672 | P2 |
Active, not recruiting |
Endometrioid Carcinoma|Endometrial Cancer|Serous Cystadenocarcinoma|Uterine Cancer |
2024-12-31 |
|
| CEDUVEAL-M | P2 |
Active, not recruiting |
Uveal Melanoma |
2023-03-02 |
|
| NCI-2021-00615 | P2 |
Active, not recruiting |
Mucinous Adenocarcinoma|Clear Cell Adenocarcinoma|Serous Cystadenocarcinoma|Endometrioid Carcinoma|Transitional Cell Carcinoma|Mucinous Cystadenocarcinoma|Peritoneal Cancer|Ovarian Cancer |
2023-01-26 |